| |
|
| |
 |
| |
| Board Of Directors - Acunova Life Sciences Inc |
| |
| |
|
 |
 |
| |
|
Dr. Dinesh Patel
Chairman
| Close |
|
|
Dr. Dinesh Patel
Chairman
Dr. Dinesh Patel - popularly known as the father of biotechnology and pharmaceuticals in the Mountain West region, is the Chairman of the Board of Directors at Acunova Life Science Inc. Dr. Patel is a founding managing director of vSpring Capital. From 1999 to 2004 he was the Founder, Chairman, President & CEO of Ashni Naturaceuticals, Inc., a company that specializes in the research, development and marketing of clinically tested and patent-protected naturaceutical products. Prior to vSpring, he co-founded and served as Chairman and CEO of TheraTech, a biotechnology company, which was sold for $350 million to Watson Therapeutics soon after a successful IPO. Dr. Dinesh was also a Co-Founder and Founding CEO and Chairman of Salus Therapeutics. Dr. Dinesh has led investments in Altea Therapeutics, Exagen, Pharmadigm, Protolex, Q Therapeutics, and Salus Therapeutics
Dr. Patel serves on several non-profit boards, and has won numerous awards including; 2006 Ellis Island Medal of Honor, US Small Business Administration's Business Achiever Award, Scientific and Technology Award (State of Utah), Entrepreneur of the Year Award (Mountain West Venture Group) and Scientific and Technology Development Pioneer of Progress Award to name a few. He is also a charter member of The Indus Entrepreneurs (TiE). Dr. Patel served as co-chair of Governor Huntsman's transition team and is currently on the board of the Utah Policy Partnership (UPP). He was recently appointed the Chairman of the USTAR Governing Authority board.
Dr. Patel received his bachelor's degree in Pharmacy at Gujarat University, (Ahmedabad) and his master's degree from the Philadelphia College of Pharmacy. He has received his Ph.D. in Physical Pharmacy from the University of Michigan. |
|
|
Mr. Kal Chatto
Co Founder and Director
| Close |
|
|
Mr. Kal Chatto
Co Founder and Director
Mr. Kal Chatto serves on the Board of Acunova Life Sciences Inc as an Independent Director. He served Amgen Inc for over sixteen years in diverse leadership capacities including Marketing, Training and Medical Affairs. He has the credit of being recruited from Glaxo Inc. Senior Management Team in 1988 to be one of the first 9 Amgen business development and commercialization executive leaders.
With an experience of over 24 years in the Pharmaceutical and Biotech Field, he has the achievement of contributing to the success of Amgen in making it the one of the best Biotech Company worldwide. He is also on the board of leading professional organizations and key pharmacy schools of prestigious U.S Universities.
Mr. Kal Chatto received his B.Pharm from Banaras Hindu University and M.S. in Pharmacy Administration from the Long Island University, New York. He has also completed Executive Management Programs from Marshall School of Business, USC and Anderson School of Management, UCLA. |
|
|
|
| |
|
 |
 |
| |
|
Mr. D A Prasanna
Founder and Director
| Close |
|
|
Mr. D A Prasanna
Founder and Director
As a founder, he has mapped the vision and strategy for the organization. He has experience in leveraging Asian competitiveness building successful global business in medical technology for GE and software for Wipro. As Exec Chairman of the Manipal Group, his focus was on developing a research thrust for the Group. Considered a thought leader in Health care and Life Sciences, he has worked in global leadership positions in GE and was Vice Chairman of Wipro. He serves on the board of various Pharma companies and Research institutes.
Prasanna is acknowledged in the healthcare sector as the pioneer in creating a market for high tech. medical equipment and delivering clinical excellence at low patient fees in Asian Hospitals, through innovative strategies. As the startup CEO of GE Medical in India, he also developed a $330 m Global Business in healthcare for GE Medical Systems (GEMS) by leveraging India's competitiveness taking the company from no 5 to No 1. He has also been a founding member of Wipro's team that initiated the company's entry into IT and was Vice Chairman of Wipro Ltd.
He is an independent Director of Take Solutions Ltd. He serves on the Governing Council of Center for Policy Research, India's leading Think Tank and of T A Pai Management Institute, a reputed Business School. He is a Trustee on Shriram Ownership Trust, which shapes the strategy of Shriram group of companies. He has served as Chairman of GEBEL, GEMS IT Ltd and GE X-Ray(South Asia) and Director of GE Yokogawa Medical Systems Ltd, Japan and GE Samsung Ltd, Korea, Wipro GE Medical Systems Ltd, India and Shasun Chemical & Drugs Ltd India. He brings rich experience in pharma and healthcare.
Mr. Prasanna is an alumnus of IIM Ahmedabad & GE Global Business Leadership Program at Crotonville. |
|
|
Dr. Kohkan Shamsi
Director
| Close |
|
|
Dr. Kohkan Shamsi
Director
Kohkan Shamsi MD, PhD is a radiologist and has more than 20 years of pharmaceutical, regulatory, clinical and academic experience.
Dr. Shamsi started his career as a Radiologist with Ministry of Health, Saudi Arabia. Then he joined the department of radiology in Antwerp University Hospital, Belgium where he completed his PhD. He moved to Berlin and worked as Research Physician in Diagnostic Imaging at Schering AG, Berlin, Germany. After working for about 5 years in Germany he was transferred to Berlex Inc. New Jersey, USA (a subsidiary of Schering AG) where he has worked for about 8 years as Senior Associate Director, Clinical Development and rose to the position of Head, Medical Development of Diagnostic Imaging & Radio pharmaceuticals & Head of Global Medical Imaging.
Dr. Shamsi has conceptualized, coordinated, and executed over 25 multi-center, international clinical trials (phase I - phase III) to develop new MRI contrast agents for oncology imaging, CNS, Magnetic Resonance Angiography and cardiac imaging. These trials were performed in Europe, the USA, South America and Australia and India. He was one of the first at Schering AG to leverage emerging markets like Latin America and India in clinical trials.
Dr. Shamsi has submitted many NDAs in Europe, USA and Japan with successful outcomes and interacts with regulatory agencies for IND, PMA, pre NDA and other regulatory meetings.
Dr Shamsi has published extensively including book, book chapter and more than 90 papers and abstracts in indexed journals. He regularly participate in various scientific forums, meetings, initiatives for image standardization, image evaluations, and image management for drug development and lectures in global meetings and conferences.
Since 2006, he has been with Ecron Acunova in leadership positions and continues to contribute to its phenomenal growth. |
|
|
| |
|
|
|
|
